Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy

Talal Hilal, Mary Nakazawa, Jacob Hodskins, John L. Villano, Aju Mathew, Guarav Goel, Lars Wagner, Susanne M. Arnold, Philip DeSimone, Lowell B. Anthony, Peter J. Hosein

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options. Methods: Patients who had CGP by a CLIA-certified laboratory between November 2012 and December 2015 were included. The medical records were analyzed retrospectively after Institutional Review Board (IRB) approval. The treating oncologist made the decision to obtain the assay to provide potential therapeutic options. The objectives of this study were to determine the proportion of patients who benefited from GDT, and to identify barriers to receiving GDT. Results: A total of 125 pediatric and adult patients with a histologically confirmed diagnosis of malignancy were included. Among these, 106 samples were from adult patients, and 19 samples were from pediatric patients. The median age was 54 years for adults. The majority had stage IV malignancy (53%) and were pretreated with 2-3 lines of therapy (45%). The median age was 8 years for pediatric patients. The majority had brain tumors (47%) and had received none or 1 line of therapy (58%) when the profiling was requested. A total of 111 (92%) patients had genomic alterations and were candidates for GDT either via on/off-label use or a clinical trial (phase 1 through 3). Fifteen patients (12%) received GDT based on these results including two patients who were referred for genomically matched phase 1 clinical trials. Three patients (2%) derived benefit from their GDT that ranged from 2 to 6 months of stable disease. Conclusions: CGP revealed potential treatment options in the majority of patients profiled. However, multiple barriers to therapy were identified, and only a small minority of the patients derived benefit from GDT.

Original languageEnglish (US)
Article number602
JournalBMC Cancer
Volume17
Issue number1
DOIs
StatePublished - Aug 30 2017

Fingerprint

Genotype
Therapeutics
Clinical Trials, Phase I
Pediatrics
Off-Label Use
Neoplasms
Research Ethics Committees
Brain Neoplasms
Medical Records

Keywords

  • Cancer therapeutics
  • Genomics
  • Genotype-directed therapy
  • Profiling

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. / Hilal, Talal; Nakazawa, Mary; Hodskins, Jacob; Villano, John L.; Mathew, Aju; Goel, Guarav; Wagner, Lars; Arnold, Susanne M.; DeSimone, Philip; Anthony, Lowell B.; Hosein, Peter J.

In: BMC Cancer, Vol. 17, No. 1, 602, 30.08.2017.

Research output: Contribution to journalArticle

Hilal, T, Nakazawa, M, Hodskins, J, Villano, JL, Mathew, A, Goel, G, Wagner, L, Arnold, SM, DeSimone, P, Anthony, LB & Hosein, PJ 2017, 'Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy', BMC Cancer, vol. 17, no. 1, 602. https://doi.org/10.1186/s12885-017-3587-8
Hilal, Talal ; Nakazawa, Mary ; Hodskins, Jacob ; Villano, John L. ; Mathew, Aju ; Goel, Guarav ; Wagner, Lars ; Arnold, Susanne M. ; DeSimone, Philip ; Anthony, Lowell B. ; Hosein, Peter J. / Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. In: BMC Cancer. 2017 ; Vol. 17, No. 1.
@article{7b960322572941e98d36565f54ae2c5d,
title = "Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy",
abstract = "Background: Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options. Methods: Patients who had CGP by a CLIA-certified laboratory between November 2012 and December 2015 were included. The medical records were analyzed retrospectively after Institutional Review Board (IRB) approval. The treating oncologist made the decision to obtain the assay to provide potential therapeutic options. The objectives of this study were to determine the proportion of patients who benefited from GDT, and to identify barriers to receiving GDT. Results: A total of 125 pediatric and adult patients with a histologically confirmed diagnosis of malignancy were included. Among these, 106 samples were from adult patients, and 19 samples were from pediatric patients. The median age was 54 years for adults. The majority had stage IV malignancy (53{\%}) and were pretreated with 2-3 lines of therapy (45{\%}). The median age was 8 years for pediatric patients. The majority had brain tumors (47{\%}) and had received none or 1 line of therapy (58{\%}) when the profiling was requested. A total of 111 (92{\%}) patients had genomic alterations and were candidates for GDT either via on/off-label use or a clinical trial (phase 1 through 3). Fifteen patients (12{\%}) received GDT based on these results including two patients who were referred for genomically matched phase 1 clinical trials. Three patients (2{\%}) derived benefit from their GDT that ranged from 2 to 6 months of stable disease. Conclusions: CGP revealed potential treatment options in the majority of patients profiled. However, multiple barriers to therapy were identified, and only a small minority of the patients derived benefit from GDT.",
keywords = "Cancer therapeutics, Genomics, Genotype-directed therapy, Profiling",
author = "Talal Hilal and Mary Nakazawa and Jacob Hodskins and Villano, {John L.} and Aju Mathew and Guarav Goel and Lars Wagner and Arnold, {Susanne M.} and Philip DeSimone and Anthony, {Lowell B.} and Hosein, {Peter J.}",
year = "2017",
month = "8",
day = "30",
doi = "10.1186/s12885-017-3587-8",
language = "English (US)",
volume = "17",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy

AU - Hilal, Talal

AU - Nakazawa, Mary

AU - Hodskins, Jacob

AU - Villano, John L.

AU - Mathew, Aju

AU - Goel, Guarav

AU - Wagner, Lars

AU - Arnold, Susanne M.

AU - DeSimone, Philip

AU - Anthony, Lowell B.

AU - Hosein, Peter J.

PY - 2017/8/30

Y1 - 2017/8/30

N2 - Background: Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options. Methods: Patients who had CGP by a CLIA-certified laboratory between November 2012 and December 2015 were included. The medical records were analyzed retrospectively after Institutional Review Board (IRB) approval. The treating oncologist made the decision to obtain the assay to provide potential therapeutic options. The objectives of this study were to determine the proportion of patients who benefited from GDT, and to identify barriers to receiving GDT. Results: A total of 125 pediatric and adult patients with a histologically confirmed diagnosis of malignancy were included. Among these, 106 samples were from adult patients, and 19 samples were from pediatric patients. The median age was 54 years for adults. The majority had stage IV malignancy (53%) and were pretreated with 2-3 lines of therapy (45%). The median age was 8 years for pediatric patients. The majority had brain tumors (47%) and had received none or 1 line of therapy (58%) when the profiling was requested. A total of 111 (92%) patients had genomic alterations and were candidates for GDT either via on/off-label use or a clinical trial (phase 1 through 3). Fifteen patients (12%) received GDT based on these results including two patients who were referred for genomically matched phase 1 clinical trials. Three patients (2%) derived benefit from their GDT that ranged from 2 to 6 months of stable disease. Conclusions: CGP revealed potential treatment options in the majority of patients profiled. However, multiple barriers to therapy were identified, and only a small minority of the patients derived benefit from GDT.

AB - Background: Describe a single-center real-world experience with comprehensive genomic profiling (CGP) to identify genotype directed therapy (GDT) options for patients with malignancies refractory to standard treatment options. Methods: Patients who had CGP by a CLIA-certified laboratory between November 2012 and December 2015 were included. The medical records were analyzed retrospectively after Institutional Review Board (IRB) approval. The treating oncologist made the decision to obtain the assay to provide potential therapeutic options. The objectives of this study were to determine the proportion of patients who benefited from GDT, and to identify barriers to receiving GDT. Results: A total of 125 pediatric and adult patients with a histologically confirmed diagnosis of malignancy were included. Among these, 106 samples were from adult patients, and 19 samples were from pediatric patients. The median age was 54 years for adults. The majority had stage IV malignancy (53%) and were pretreated with 2-3 lines of therapy (45%). The median age was 8 years for pediatric patients. The majority had brain tumors (47%) and had received none or 1 line of therapy (58%) when the profiling was requested. A total of 111 (92%) patients had genomic alterations and were candidates for GDT either via on/off-label use or a clinical trial (phase 1 through 3). Fifteen patients (12%) received GDT based on these results including two patients who were referred for genomically matched phase 1 clinical trials. Three patients (2%) derived benefit from their GDT that ranged from 2 to 6 months of stable disease. Conclusions: CGP revealed potential treatment options in the majority of patients profiled. However, multiple barriers to therapy were identified, and only a small minority of the patients derived benefit from GDT.

KW - Cancer therapeutics

KW - Genomics

KW - Genotype-directed therapy

KW - Profiling

UR - http://www.scopus.com/inward/record.url?scp=85028503939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028503939&partnerID=8YFLogxK

U2 - 10.1186/s12885-017-3587-8

DO - 10.1186/s12885-017-3587-8

M3 - Article

C2 - 28854908

AN - SCOPUS:85028503939

VL - 17

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 602

ER -